206,444 Shares in Pulmonx Co. (NASDAQ:LUNG) Bought by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC purchased a new stake in shares of Pulmonx Co. (NASDAQ:LUNG) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 206,444 shares of the company’s stock, valued at approximately $1,711,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LUNG. Squarepoint Ops LLC grew its position in Pulmonx by 261.2% during the second quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock valued at $916,000 after acquiring an additional 104,432 shares during the last quarter. Millrace Asset Group Inc. purchased a new stake in shares of Pulmonx in the 3rd quarter valued at $1,390,000. SG Americas Securities LLC bought a new stake in Pulmonx in the third quarter worth $102,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Pulmonx by 7.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock valued at $6,714,000 after buying an additional 69,595 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Pulmonx during the second quarter valued at about $222,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus dropped their price target on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.67.

Pulmonx Stock Performance

Shares of LUNG stock opened at $6.61 on Wednesday. The company’s fifty day moving average price is $6.80 and its 200-day moving average price is $6.99. The stock has a market cap of $261.03 million, a PE ratio of -4.50 and a beta of 0.69. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a 12 month low of $5.46 and a 12 month high of $14.84.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The business had revenue of $20.39 million for the quarter, compared to analysts’ expectations of $20.39 million. During the same quarter in the prior year, the company earned ($0.39) earnings per share. On average, equities analysts expect that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.63, for a total value of $132,600.00. Following the completion of the transaction, the director now owns 1,071,974 shares of the company’s stock, valued at $7,107,187.62. The trade was a 1.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have sold 60,000 shares of company stock valued at $424,800. 5.70% of the stock is currently owned by corporate insiders.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.